BioCryst 2025 revenue rises 94% on ORLADEYO sales

BioCryst Pharmaceuticals

26/02/2026 12:19

Overview

Biotechnology firm's 2025 revenue rose 94%, driven by U.S. ORLADEYO sales

Company achieved record GAAP and non-GAAP operating profit for 2025

Company completed acquisition of Astria Therapeutics, expanding HAE portfolio

Outlook

Company maintains 2026 ORLADEYO revenue guidance at $625 mln to $645 mln

Company expects 2026 total revenue between $635 mln and $660 mln

Company anticipates 2026 non-GAAP operating expenses of $450 mln to $470 mln

Result Drivers

U.S. ORLADEYO SALES - Strong U.S. sales drove 2025 revenue growth following the sale of European business

FDA APPROVAL - FDA approved ORLADEYO oral pellets for children with HAE, enhancing treatment options

ACQUISITION OF ASTRIA - Acquisition of Astria Therapeutics expanded HAE portfolio with navenibart

Company press release: ID:nGNX7DPnx2

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
$1.12


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for BioCryst Pharmaceuticals Inc is $19.50, about 158.3% above its February 25 closing price of $7.55

The stock recently traded at 19 times the next 12-month earnings vs. a P/E of 25 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)